TWiV explains a study of how climate change is predicted to increase cross-species viral transmission risk, and increased memory B cell potency and breadth after a SARS-CoV-2 mRNA vaccine boost.
In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.
TWiV explains what is known about cases of acute, severe hepatitis of unknown origin in children, and discovery of an inhibitor of TMPRSS2 protease that blocks SARS-CoV-2 infection.
Kartik, Denise, and Gorka join TWiV to discuss their finding that changes in the surface glycoprotein of South American yellow fever virus lead to reduced neutralization by antibodies induced by the vaccine, which is derived from an African isolate.
In COVID-19 clinical update #111, Dr. Griffin discusses vaccine coverage and mortality in Hong Kong, immune response to boosters in kids, hospitalization of kids, breath based diagnostic test, viral co-infections, bivalent mRNA vaccine, intramuscular Evusheld, and global long COVID.
Elke, Adam, and Gabor join TWiV to discuss their work on Lloviu virus, a filovirus, including recovery of infectious virus from a DNA copy of the genome and from Schreiber’s bats in Hungary.
In COVID-19 clinical update #110, Dr. Griffin covers hospital admissions during variant outbreaks, viral load in vaccinated and unvaccinated individuals, predictive capacity of symptoms in children, comparison of antigen tests, incidence of myocarditis after vaccination, steroids during replication phase, Paxlovid efficacy and safety, fluvoxamine, sabizabutin, colchicine, and prevalence of infection in Africa.
Richard joins TWiV to discuss the SARS-CoV-2 antiviral drug Molnupiravir , including how it was discovered, its mechanism of action, whether it is a mutagen for cells, and the future of drugs for treatment of COVID-19.
TWiV explains why this season’s influenza vaccine is not protecting against mild to moderate disease caused by H3N2 virus, and that antibody-dependent entry of SARS-CoV-2 into monocytes is a major contributor to severe COVID-19.
In COVID-19 clinical update #109, Daniel Griffin discusses cardiac complications after infection or vaccination, long COVID in children, fourth vaccine dose in Israel, no need for fourth vaccine dose in EU, dexamethasone dosing, immunomodulation therapy, MIS outcomes in children, US long COVID effort launched, and herd immunity.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Rich Condit, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.